首页> 外文期刊>Saudi Journal of Biological Sciences >Clinical efficacy of intravenous infusion of atropine with micropump in combination with hemoperfusion on organophosphorus poisoning
【24h】

Clinical efficacy of intravenous infusion of atropine with micropump in combination with hemoperfusion on organophosphorus poisoning

机译:静脉注射阿里博与微泵与有机磷中毒血液灌浆结合的临床疗效

获取原文
       

摘要

Objective To observe the clinical efficacy of intravenous infusion of atropine with micropump in combination with hemoperfusion on organophosphorus poisoning patients, and investigate the potential mechanism. Methods In this study, we enrolled 136 organophosphorus poisoning patients who received treatment in this hospital between January 2009 and December 2017, and they were divided into three groups according to the clinical treatment methods, i.e. Group A (comprehensive treatment with HP, n?=?47), Group B (continuous intravenous infusion of atropine with micropump, n?=?43) and Group C (regular intravenous infusion of atropine, n?=?46). In addition to the close monitoring of vital signs, we recorded the atropinization time (min), cholinesterase reactivation time (h), total dose of atropine, recurrence, incidence rate of atropine poisoning (%), hospitalization time (d) and cure rate (%). Results In comparison with Group C, patients in Group A and B manifested more stable vital signs with lower total dose of atropine and incidence rate of atropine poisoning and shorter cholinesterase reactivation time, while the cure rate was remarkably increased ( p? ?0.05), and no significant differences were observed in atropinization time among three groups ( p? ?0.05). Compared to Group B and C, total dose of atropine in Group A was significantly decreased with obvious excellence in hospitalization time, reduction of complications and increases in cure rates ( p? ?0.05). Moreover, patients in Group A had the lowest mortality rate among three groups. Conclusion In treatment of organophosphorus poisoning patients, HP and continuous intravenous infusion of atropine using micropump can elevate the survival rate, reduce the incidence of adverse reaction, shorten the reactivation time of cholinesterase and decrease the incidence rate of complications, which are superior to the traditional treatment method.
机译:目的观察静脉注射阿托品与微泵与有机磷中毒患者血液灌浆的临床疗效,研究潜在机制。本研究的方法,我们在2009年1月至2017年1月在本医院接受了136名有机磷中毒患者,并根据临床治疗方法分为三组,即A组(综合治疗HP,N?= α47),B组(连续静脉内输注与微泵的阿托品,N?= 43)和C组(常规静脉输注阿托品,N?= 46)。除了对生命体征的密切监测外,我们记录了阿甲化时间(分钟),胆碱酯酶重新激活时间(h),总剂量的阿托品,复发,阿托品中毒发生率(%),住院时间(d)和治愈率(%)。结果与C组,A组和B组患者表现出更稳定的生命体征,其少量的阿托品和阿托品中毒发生率和较短的胆碱酯酶重新激活时间,而固化率显着增加(P?<?0.05)并且在三组的阿托透明时间中没有观察到显着差异(p?> 0.05)。与B组和C组相比,A组中的Atropine总剂量随着住院时间的明显卓越而显着降低,减少并发症和治愈率增加(P?<?0.05)。此外,A组患者在三组中具有最低的死亡率。结论在有机磷中毒患者的治疗中,HP和使用微泵连续静脉内输注使用微泵可以提高存活率,降低不良反应的发生率,缩短胆碱酯酶的再活化时间并降低并发症发病率,从而优于传统治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号